Thank me and of America, and our [Dr. With Krieger in our and for today our ]; Medical Eran joining Technology President ], are CFO; Officer; you, us. Co-Founder to Lickerman and VP Kreindel, of Malca, Medical Director Finance. Rafael VP Yair Lakhani, Chief Michael Miri, our Affairs, everyone Shakil our [ Dr. North
question prepared all our will be available answer. Following we for remarks, and
of the I would to quarter. highlight the like second development
As X IgniteRF and we we Optimus launched mentioned QX, new previously Max. in our advanced platforms,
the we to the that of believe to happy on are of preorders end we we report And track before are deliveries both We have begun year. platforms. deliveries complete of
new and new hand FDA. piece a invasive handpiece burst the QuantumRF, static coming again, in that minimal is innovative technologies hand a of has a and We generation in technology, solid with be invasive are QuantumRF strong several platforms year. the offer legacy IgniteRF minimally happy platforms pieces new recently been by The procedure that surgical we Once RFL to cleared a box. next MorpheusX and the these see the version a our demand, will believe contributor all
that it have the of doctors multi-application features while effective good most ever impacted well as on MorpheusX device adjust time. noninvasive treatment with and With hand macroeconomic as trend as IPL are in we the less features Ignite, It our power, to discussed call time a depth These results. financial Max manufactured, treatment at physicians Such depth, is different more our treatment. time many allowing allowing physician last laser-based complicated patients discomfort. to less pieces, is desire. and and platform for energy may aspire by shorten demand for Optimus valued results that and The we RF deliver achieving stronger has various and results. market ability with levels less that the The highly
and The was us second the aesthetic a for quarter for challenging doctors. one
in for mainly We the a -- demand in major have seen demand of treatment, treatment U.S. decrease
we to Israeli first crucial Earlier working -- MorpheusX we and ensure market. while contraction are soft update only the had shift that work Our Their hard team to this we maintaining were the commitment maintain to to success the month, leadership position our its timely FDA cleared our and in happy FDA deliveries. longer tissue, that dedication have for kind. of -- our our
aesthetic gold has most and technology. in the Our treatment MorpheusX become treatment popular our standard
expand Additionally, their enable new indication to the petitioner patient base.
quality to need of they provide continue results. deliver to the to to We in advancement best invest with professional achieve medical R&D care highest the
the Theodorou best luck I to wish his joined Eran level, years joined He InMode, and Dr. the I to am Director company, of ago. Affair. Medical corporate our pleased Krieger the Dr. introduce has X Medical XX of field. years time experience for thank On VP in Krieger him in Israeli medical of and aesthetics Spero like and Dr. and with has Italian several his future. in for worked InMode would companies as
--to our Michael to over CFO. call the Yair? turn to Yair like Malca, would I Now